Extended-release niacin raises adiponectin and leptin.

Area of Science:

• Endocrinology
• Metabolic Syndrome Research
• Cardiovascular Disease Research

Background:

• Niacin, a lipid-lowering drug, is gaining attention for raising HDL-cholesterol and slowing intima-media thickness progression in coronary heart disease patients.
• Niacin's known action on adipocytes prompted an investigation into its effects on adipokines and their associated functions.

Purpose of the Study:

• To investigate the impact of extended-release niacin on adipokines and their related functions in men with metabolic syndrome.
• To assess whether niacin improves insulin sensitivity, anti-inflammatory markers, and endothelial function.

Main Methods:

• A 6-week randomized, placebo-controlled, double-blind study involving 30 men with metabolic syndrome.
• Participants received either 1500 mg of extended-release niacin (n=20) or a placebo (n=10).
• Measurements included adiponectin, leptin, resistin, TNF-alpha, IL-6, high-sensitivity CRP, endothelial function, and HOMA index.

Main Results:

• Extended-release niacin significantly increased adiponectin (56%) and leptin (26.8%) levels.
• Resistin, TNF-alpha, IL-6, and high-sensitivity CRP levels remained unchanged.
• No improvement in endothelial function was observed; the HOMA index (insulin resistance) significantly deteriorated by 42%.

Conclusions:

• Short-term niacin treatment markedly increases adiponectin but does not enhance atheroprotective functions.
• Niacin failed to improve insulin sensitivity, anti-inflammatory effects, or endothelial function in this cohort.
• The study indicates potential limitations of niacin in improving key metabolic and cardiovascular markers despite adipokine modulation.